Drug Trial Radar · NCT06723652
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Feb 13, 2025
Primary completion
Aug 25, 2025
Study completion Nov 18, 2025
Sponsor
- Lead sponsor
- Beijing Suncadia Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with homozygous familial hypercholesterolemia (HoFH).
Conditions
- Homozygous Familial Hypercholesterolemia
Interventions
SHR-1918Drug
six administration
SHR-1918 placeboDrug
SHR-1918 placebo three administration+SHR-1918 three administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in calculated LDL-C from baseline to week 12Time frame: week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Xiangya Hospital of Central South University Hospital
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.